A federal district court in Delaware ruled that Viatris’ product, currently awaiting approval from the US Food and Drug Administration (FDA), does not infringe on Novo Nordisk’s patent for the ...

Can it really be maintained after they’re discontinued on top-selling drugs such as Ozempic or Wegovy, or is rebound weight gain simply a natural part of the process? For many adult patients taking ...

People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

The researchers first tested their hypothesis by delivering ODN directly to the hindbrain of rats. Once treated, the rats ...

More studies are needed, but patients should consider adding exercise and ensure adequate protein intake to maximize the ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Older adults and women using Wegovy for obesity management may be more likely to lose lean mass, although increasing protein intake may help protect against lean mass loss, according to a speaker.

The hormonal changes of menopause can make the weight gain more resistant to traditional diet and lifestyle changes. But GLP-1s can be an effective reinforcement of diet and exercise.